Navigation Links
Right warfarin dose determined by 3 genes
Date:3/20/2009

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics.

"We have previously studied selected genes that can affect warfarin treatment. Now that we have gone in and scanned the entire genome, we see that the two most important genes are among those we previously singled out," says Mia Wadelius, a researcher at Uppsala University, and one of the scientists behind the study.

She also says that this is the first truly large warfarin study in which all genes were reviewed at the same time. More than 1,000 warfarin patients and roughly 370,000 gene variants, covering the entire human genome, were studied.

"The adequate warfarin dosage for a patient is determined by three genes: VKORC1, CYP2C9, and CYP4F2. This is a step forward for a large group of patients, because it will be easier to determine the dosage, and the treatment will be less risky," says Mia Wadelius.

Patients vary in their sensitivity to warfarin, which makes treatment initially a risky balancing act between bleeding and blood clots. Mia Wadelius says that the variation is great among patients, sometimes up to a difference of twenty times. But now that researchers have managed to identify which genes underlie this variation, it will be possible to predict different patients' needs for warfarin more precisely, rendering treatment safer. The next step is to look for markers for bleeding.

"We will continue to look for genetic variants that influence the risk of bleeding, which can be a reaction to warfarin treatment, though a rare one. The findings of the Swedish study will be combined with those from a British study in order to attain a sufficiently robust analysis of risks of bleeding," says Mia Wadelius.


'/>"/>

Contact: Mia Wadelius
mia.wadelius@medsci.uu.se
46-018-611-4945
Uppsala University
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. Stressed-Out Moms Carry Babies on the Right
2. Bright tumors, dim prospects
3. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
4. Right breakfast bread keeps blood sugar in check all day
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Experts Agree. Ohios Technology Investment Future Looks Bright
7. L.A. Playwright Creates an Enormous Wave with His New Book, Touch the Ocean
8. Civil Rights and Medical Leaders Call for Social Justice in Health Care
9. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
10. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
11. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... pinpoint seven that increase susceptibility to disease , , ... associated with increased susceptibility to leprosy have been ... The researchers, who analyzed more than 10,000 DNA ... China, said their discovery highlights the important role ... development of leprosy. , "Though leprosy is not ...
(Date:12/16/2009)... Florida researchers at work on a malaria elimination study ... spread of the disease using cell phone records. , ... determine how often residents of Zanzibar travel and where ... off the coast of Tanzania in East Africa, Zanzibar ... commissioned the study as part of deliberations on whether ...
(Date:12/16/2009)... animals, they cut bleeding time in half, but use in ... News) -- Hoping to improve on nature, researchers have built ... to be used in trauma or other cases where blood ... core, with material that is used in degradable stitches, which ... of biomedical engineering at Case Western Reserve University, and lead ...
(Date:12/16/2009)... BioSpace and MassBio promote Massachusetts companies through annual marketing campaign ... ... 16, 2009 -- BioSpace unveiled the 2010 Genetown™ Hotbed ... sciences., , , , ,Genetown is sponsored by MassBio ... medical device industries. The campaign places each entity’s brand on ...
(Date:12/16/2009)... Dec. 16 Shoppers like knowing if ... or Argentina. But grocers have found it burdensome ... (COOL) laws requiring them to provide the information ... at easyCOOLnow.com for easily making grocery ... include provisions that require retailers of unprocessed fruits, ...
Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:New Website Helps Grocers Comply With COOL Laws 2
... since 1950 had agreement on standard outcomes, review finds ... consider the appropriate measurements for assessing drug clinical trials ... reviewed 9,000 pediatric clinical trials conducted since 1950. , ... and none have involved children in the process to ...
... more realistically according to a new study accepted for ... (JCEM). The study revealed that anti-Mllerian hormone (AMH) levels ... able to specify a womans reproductive age more accurately ... in the blood reflect the number of small follicles ...
... Tenn., April 29, 2008 HCA announces the,following Webcast:, What: ... May 6, 2008 @ 9:00am CT, Where: ... Internet -- Simply log on to the web at the ... If you are unable to participate during the live webcast, the call ...
... today announced that Robert Palmisano, president and chief executive,officer, is ... on Tuesday, May 13, 2008 at 4:00 p.m. PT (7:00 ... Healthcare Conference will be held at,the Four Seasons Hotel in ... the investors, section of the ev3 Web site,at http://www.ev3.net ...
... 29 More than 50,000 doctors,have given 20 ... in,poverty, thanks to Reach Out and Read. Partnering ... literacy advice to their parents at check-ups, Reach,Out ... U.S. infants, toddlers,and preschoolers. The children,s literacy program ...
... Trip Than Having Own Toothbrush, PRINCETON, N.J., April ... do men and women feel comfortable sharing their,toothbrush with ... brushing,their teeth for a week or not shaving their ... powered toothbrushes become more popular, what do,Americans feel is ...
Other Medicine News:Health News:Measurements Poor for Assessing Clinical Trials With Children 2Health News:20 Million Kids' Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read 2Health News:Crest(R) SPINBRUSH(R) Oral Hygiene Survey Reveals "Nothin' but the Tooth" 2Health News:Crest(R) SPINBRUSH(R) Oral Hygiene Survey Reveals "Nothin' but the Tooth" 3Health News:Crest(R) SPINBRUSH(R) Oral Hygiene Survey Reveals "Nothin' but the Tooth" 4
(Date:12/16/2009)... 16 BioSpecifics Technologies Corp. (Nasdaq: ... class collagenase-based products, today announced top-line efficacy and ... of XIAFLEX(TM) for the treatment of Peyronie,s disease. ... inelastic collagen on the shaft of the penis, ... intercourse difficult or impossible in advanced cases. The ...
(Date:12/16/2009)... R.I., Dec. 16 CVS/pharmacy and MinuteClinic ... are now offering H1N1 vaccine in 20 states ... priority restrictions for receiving H1N1 vaccines continue, many ... be eligible to receive the shot while supplies ... been restocked and is available at MinuteClinic locations ...
(Date:12/16/2009)... -- Vivakor, Inc. (OTC Bulletin Board: VIVK) ... Baker Consulting out of Walnut Creek, California ... out of South Florida. Baker Consulting ... with business development, financing and assisting the ... Specifically, Baker Consulting is exploring potential acquisition ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Vivakor Signs Business Development Agreement With Baker Consulting 2Sevocity Launches EHR 28Electronic Health Record 29 Interface With Austin Radiological Association 50278 1Sevocity Launches EHR 28Electronic Health Record 29 Interface With Austin Radiological Association 50278 2Sevocity Launches EHR 28Electronic Health Record 29 Interface With Austin Radiological Association 50278 3DuoCort 3A New chronotherapy for adrenal insufficiency 9039 1DuoCort 3A New chronotherapy for adrenal insufficiency 9039 2DuoCort 3A New chronotherapy for adrenal insufficiency 9039 3Look Good Feel Better and OPI Celebrate 20 Years of Helping Women Cope With Cancer 50273 1Look Good Feel Better and OPI Celebrate 20 Years of Helping Women Cope With Cancer 50273 2
... N.J., Nov. 26 Schering-Plough,Corporation (NYSE: SGP ... Drug,Administration (FDA) recently accepted the filing for review ... fast-dissolving, sublingual tablet.,Schering-Plough is seeking marketing approval from ... mania or mixed episodes associated with Bipolar I,Disorder. ...
... YORK, Nov. 23 At a media event held ... New York, prominent lasik,surgeons Drs. Joseph and Jeffrey Dello ... maker Alcon, which goes "beyond Custom-cornea"., Since Dr. ... nation,in 1990, he has long been associated with the ...
Other Medicine Technology:Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 2Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 3Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 4
... OL1000 Bone Growth Stimulators are portable, ... the noninvasive treatment of an established nonunion ... vertebrae and flat bones. ... chance of healing of 60.7% in patients ...
... EBI OsteoGen surgically implanted bone growth stimulator is ... when surgery is already planned or when patient ... is totally surgically implanted, patients are assured of ... hours a day for up to 6 months. ...
BioScrew® Bio-Absorbable Interference Screws and Delivery System Clinically equivalent to metal interference screws....
Cannulated Interference Screws...
Medicine Products: